Basso Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Basso Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-28,538	Closed	-$2.84M	–	500
2021 Q2	$2.84M	Buy	28,538 +255	+0.9%	+$25.3K	0.36%	94
2021 Q1	$2.8M	Buy	28,283 +16,646	+143%	+$1.69M	0.43%	88
2020 Q4	$1.17M	Sell	11,637 -2,500	-18%	-$249K	0.29%	82
2020 Q3	$1.4M	Buy	14,137 +7,158	+103%	+$715K	0.49%	59
2020 Q2	$715K	Sell	6,979 -766	-10%	-$74.9K	0.22%	93
2020 Q1	$736K	Buy	+7,745	New	+$758K	0.18%	114

Other funds holding JSPR

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPARFS

Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54K AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Basso Capital Management's JSPR Position: Q3 2021 in Review

Basso Capital Management sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 28,538 shares — an estimated $2.84M sold.

Basso Capital Management first reported a position in JSPR in Q1 2020 and held it in 6 quarters. The position peaked at $2.84M in Q2 2021. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

Basso Capital Management reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
Basso Capital Management sold 28,538 Jasper Therapeutics shares in Q3 2021, an estimated $2.84M.
Basso Capital Management first reported a position in Jasper Therapeutics in Q1 2020 and held it in 6 quarters.
Basso Capital Management's Jasper Therapeutics position peaked at $2.84M in Q2 2021.
10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on Basso Capital Management's 13F filing for Q3 2021, filed 9 Nov 2021.